Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report
Levy, G.; Elkas, J.; Armstrong, A.Y.; Nieman, L.K.
Journal of Reproductive Medicine 61(3-4): 159-162
2016
ISSN/ISBN: 0024-7758 PMID: 27172639 Document Number: 686039
Prolonged exposure to a selective progesterone receptor modulator (ulipristal acetate) in a patient with benign metastasizing leiomyoma did not result in endometrial hyperplasia or neoplasia. A woman with history of benign metastasizing leiomyoma underwent medical treatment for 5 years with ulipristal acetate. Endometrial biopsies were performed at established intervals to monitor for intraepithelial neoplasia or progesterone receptor modulator-associated endometrial changes (PAECs). The patient tolerated UPA therapy well; there was no evidence of hyperplasia or proliferative changes associated with progesterone-associated endometrial changes. In this case prolonged exposure to ulipristal acetate did not result in premalignant or malignant endometrial pathology.